MX383558B - Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco - Google Patents
Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmacoInfo
- Publication number
- MX383558B MX383558B MX2018001686A MX2018001686A MX383558B MX 383558 B MX383558 B MX 383558B MX 2018001686 A MX2018001686 A MX 2018001686A MX 2018001686 A MX2018001686 A MX 2018001686A MX 383558 B MX383558 B MX 383558B
- Authority
- MX
- Mexico
- Prior art keywords
- capped
- adcs
- antibodies
- antibody
- uncapped
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un proceso de producción de anticuerpo en células de mamífero en donde residuos de cisteína sin par manipulados se modifican y tapan de forma post - transferente con entidades químicas particulares, los cuales anticuerpos con capuchón son bien adecuados para más pasos de conjugación específicos de sitio para formar conjugados de anticuerpo- fármaco (ADCs) o conjugados de proteína fármaco; los ADCs producidos usando estos anticuerpos con capuchón incluyendo e n par t i c u lar ADCs formados por la reducción selectiva de los residuos de cisteína de los anticuerpos con capuchón, y los ADCs formados usando mangos químicos tales como grupos biortogonales de aldehído/azida/alquino, que permiten química de conjugación de fármaco adicional ; y anticuerpos sin capuchón producido s por células en medio de cisteína, cistina y glutationa bajo, y ADCs producidos vía conjugación di recta a estos anticuerpos sin capuchón.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204005P | 2015-08-12 | 2015-08-12 | |
| PCT/IB2016/054789 WO2017025897A2 (en) | 2015-08-12 | 2016-08-09 | Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001686A MX2018001686A (es) | 2019-01-31 |
| MX383558B true MX383558B (es) | 2025-03-14 |
Family
ID=56855760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001686A MX383558B (es) | 2015-08-12 | 2016-08-09 | Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10653794B2 (es) |
| EP (2) | EP3808768A1 (es) |
| JP (2) | JP6865209B2 (es) |
| KR (2) | KR102146617B1 (es) |
| CN (1) | CN107849121B (es) |
| AU (1) | AU2016305331B2 (es) |
| CA (1) | CA2938333A1 (es) |
| DK (1) | DK3334760T3 (es) |
| ES (1) | ES2864842T3 (es) |
| HR (1) | HRP20210579T1 (es) |
| HU (1) | HUE053956T2 (es) |
| IL (1) | IL257420B (es) |
| MX (1) | MX383558B (es) |
| PL (1) | PL3334760T3 (es) |
| PT (1) | PT3334760T (es) |
| RU (2) | RU2742260C2 (es) |
| SI (1) | SI3334760T1 (es) |
| WO (1) | WO2017025897A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2938333A1 (en) * | 2015-08-12 | 2017-02-12 | Pfizer Inc. | Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation |
| MX2019009372A (es) * | 2017-02-08 | 2019-12-11 | Pfizer | Produccion a gran escala para cisteinas de anticuerpo protegidas y no protegidas y su uso en la conjugacion de proteinas terapeuticas. |
| MA68842B1 (fr) * | 2017-08-04 | 2025-01-31 | Amgen Inc. | Procédé de conjugaison de cys-mabs |
| US20230010108A1 (en) * | 2018-10-12 | 2023-01-12 | Hangzhou Dac Biotech Co., Ltd. | A conjugation linker containing 2,3-diaminosuccinyl group |
| US12109273B2 (en) | 2019-02-15 | 2024-10-08 | Wuxi Xdc Singapore Private Limited | Process for preparing antibody-drug conjugates with improved homogeneity |
| JP7232925B2 (ja) | 2019-02-15 | 2023-03-03 | ウーシー バイオロジクス アイルランド リミテッド | 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス |
| AU2020240310A1 (en) * | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
| CN116635416A (zh) * | 2020-12-22 | 2023-08-22 | 诺华股份有限公司 | 用于在细胞培养期间降低分泌的重组表达蛋白质中半胱氨酸残基的氧化水平的方法 |
| AU2022258829A1 (en) * | 2021-04-16 | 2023-10-26 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
| WO2023067626A1 (en) * | 2021-10-20 | 2023-04-27 | Dr. Reddy's Laboratories Limited | A cell culture process to produce an antibody composition |
| KR20260052949A (ko) * | 2023-08-11 | 2026-04-20 | 암젠 인크 | 고체상 항체 접합 방법 |
| WO2026071051A1 (ja) * | 2024-09-27 | 2026-04-02 | 東レ株式会社 | 免疫グロブリンまたはその抗原結合性断片のキャップ除去のための還元剤 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5241078A (en) * | 1988-06-14 | 1993-08-31 | Cetus Oncology | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| EP0604580A1 (en) * | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| AU775937B2 (en) * | 1999-01-14 | 2004-08-19 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| WO2003048357A1 (fr) * | 2001-12-04 | 2003-06-12 | Mitsubishi Pharma Corporation | Procede d'activation de proteine |
| US8633300B2 (en) * | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| EP2021397A4 (en) * | 2006-05-26 | 2012-01-04 | Ipsen Pharma | PROCESS FOR POTENTIAL PEGYLATION |
| US8612161B2 (en) * | 2008-03-19 | 2013-12-17 | Intelligent Biosystems Inc. | Methods and compositions for base calling nucleic acids |
| EP2586788B1 (en) * | 2007-07-09 | 2017-11-29 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
| KR20100107501A (ko) * | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
| CA2766409C (en) | 2009-07-03 | 2023-04-25 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
| EP2483289B2 (en) * | 2009-10-02 | 2025-03-26 | Biogen MA Inc. | Methods of preventing and removing trisulfide bonds |
| CA2781682A1 (en) * | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| CA3220104A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| RU2661764C2 (ru) * | 2011-05-27 | 2018-07-19 | Эббви Байотекнолоджи Лтд., | Композиции и способы на основе dac hyp |
| RU2582259C2 (ru) * | 2012-02-24 | 2016-04-20 | Алтеоген Инк. | Модифицированные антитела, с которыми связан мотив, включающий остаток цистеина, конъюгаты этих модифицированных антител с лекарственными веществами и способ их получения |
| WO2014052650A2 (en) | 2012-09-26 | 2014-04-03 | Massachusetts Institute Of Technology | Modification of peptides via snar reactions of thiols with fluorinated aromatics |
| RU2016119491A (ru) * | 2013-11-04 | 2017-12-11 | Пфайзер Инк. | Конъюгаты антитела к efna4 с лекарственным средством |
| EP3077522A1 (en) * | 2013-12-04 | 2016-10-12 | Immunogen, Inc. | Compositions and methods for antibody production |
| SG11201605437YA (en) | 2014-01-27 | 2016-08-30 | Pfizer | Bifunctional cytotoxic agents |
| KR102046862B1 (ko) | 2015-03-20 | 2019-11-20 | 화이자 인코포레이티드 | Cti 약물작용발생단을 함유하는 이관능성 세포독성제 |
| CA2938333A1 (en) * | 2015-08-12 | 2017-02-12 | Pfizer Inc. | Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation |
-
2016
- 2016-08-09 CA CA2938333A patent/CA2938333A1/en active Pending
- 2016-08-09 PT PT167605484T patent/PT3334760T/pt unknown
- 2016-08-09 US US15/748,268 patent/US10653794B2/en active Active
- 2016-08-09 RU RU2018105128A patent/RU2742260C2/ru active
- 2016-08-09 EP EP20207006.6A patent/EP3808768A1/en active Pending
- 2016-08-09 PL PL16760548T patent/PL3334760T3/pl unknown
- 2016-08-09 HR HRP20210579TT patent/HRP20210579T1/hr unknown
- 2016-08-09 AU AU2016305331A patent/AU2016305331B2/en active Active
- 2016-08-09 JP JP2018506438A patent/JP6865209B2/ja active Active
- 2016-08-09 EP EP16760548.4A patent/EP3334760B1/en active Active
- 2016-08-09 CN CN201680047377.XA patent/CN107849121B/zh active Active
- 2016-08-09 IL IL257420A patent/IL257420B/en unknown
- 2016-08-09 RU RU2021101009A patent/RU2021101009A/ru unknown
- 2016-08-09 HU HUE16760548A patent/HUE053956T2/hu unknown
- 2016-08-09 KR KR1020187006927A patent/KR102146617B1/ko active Active
- 2016-08-09 KR KR1020207023230A patent/KR102319622B1/ko active Active
- 2016-08-09 MX MX2018001686A patent/MX383558B/es unknown
- 2016-08-09 SI SI201631163T patent/SI3334760T1/sl unknown
- 2016-08-09 DK DK16760548.4T patent/DK3334760T3/da active
- 2016-08-09 WO PCT/IB2016/054789 patent/WO2017025897A2/en not_active Ceased
- 2016-08-09 ES ES16760548T patent/ES2864842T3/es active Active
-
2020
- 2020-03-03 US US16/807,375 patent/US11980669B2/en active Active
-
2021
- 2021-04-05 JP JP2021063975A patent/JP2021118694A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017025897A3 (en) | Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation | |
| Cai et al. | Neoproterozoic subduction along the Ailaoshan zone, South China: Geochronological and geochemical evidence from amphibolite | |
| PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
| Sandvig et al. | Lipid requirements for entry of protein toxins into cells | |
| MX2016004564A (es) | Cultivo celular metabolicamente optimizado. | |
| EP4653013A3 (en) | Methods and compositions for modified t cells | |
| MY176822A (en) | Anti-pd-1 antibody and use thereof | |
| MY206284A (en) | Anti-cd63 antibodies, conjugates, and uses thereof | |
| MX2009003306A (es) | Anticuerpos humanos que se unen a cxcr4 y sus usos. | |
| MX2018011383A (es) | Replicon de arn para la expresion genica versatil y eficiente. | |
| PE20200839A1 (es) | Anticuerpos anti-cd137 | |
| SA520411849B1 (ar) | أجسام مضادة ومتقارنات جسم مضاد مع عقار نوعية من أجل cd123 واستخداماتها | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| PH12019502730A1 (en) | Method of manufacturing bispecific antibodies and therapeutic use of such antibodies | |
| SG10201808523RA (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
| PE20161324A1 (es) | Proteinas de fusion de interleucina-2 y usos de las mismas | |
| MX2020002791A (es) | Reduccion selectiva de proteinas. | |
| TW200833713A (en) | Human antibodies that bind CD19 and uses thereof | |
| SG10201807736SA (en) | Composition and method for stabilizing nucleic acids in biological samples | |
| PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
| PH12015500284A1 (en) | Interleukin-10 fusion proteins and uses thereof | |
| MY197322A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ713602A (en) | Method for refining protein including self-cutting cassette and use thereof | |
| WO2014204988A3 (en) | 5t4-targeted immunofusion molecule and methods | |
| WO2017070654A8 (en) | Programmable universal cell receptors and methods of using the same |